CS
OREX

Candriam SCA’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Candriam SCA’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-64,700
Closed -$1.36M – 672
2015
Q3 		$1.36M Buy
64,700
+1,200
+2% +$41.1K 0.03% 392
2015
Q2 		$3.14M Hold
63,500
– – 0.07% 306
2015
Q1 		$4.97M Buy
+63,500
New +$3.94M 0.1% 255

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Candriam SCA's OREX Position: Q4 2015 in Review

Candriam SCA sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2015, closing a stake of 64,700 shares — an estimated $1.36M sold.

Candriam SCA first reported a position in OREX in Q1 2015 and held it in 3 quarters. The position peaked at $4.97M in Q1 2015. 121 funds tracked by Wall St. Rank hold OREX as of Q4 2015.

  • Candriam SCA reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Candriam SCA sold 64,700 Orexigen Therapeutics, Inc. shares in Q4 2015, an estimated $1.36M.
  • Candriam SCA first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
  • Candriam SCA's Orexigen Therapeutics, Inc. position peaked at $4.97M in Q1 2015.
  • 121 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2015.

Based on Candriam SCA's 13F filing for Q4 2015, filed 25 Jan 2016.